David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on X:
“At Cal Cancer Consortium conference, Jonathan Riess shows impact of baseline positive vs negative plasma ctDNA for EGFR in the FLAURA2 trial. Addition of chemo to Osi mainly benefitting those with positive ctDNA. Food for thought!”
Source: David Gandara/X